Analytical Data
-
Gene name
RUNX1T1
- Application
-
Alternative Names
Cyclin-D-related protein (Eight twenty one protein) (Protein ETO) (Protein MTG8) (Zinc finger MYND domain-containing protein 2)
-
Species
Human
-
Source
E. coli
-
Tag
N- His & C- Myc
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q06455
-
Expression Region
1-604aa
-
Molecular Weight
75 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
RUNX1T1, also known as the Core Binding Factor Beta (CBFβ), is a crucial protein that plays a significant role in hematopoiesis and the regulation of gene expression. The study of RUNX1T1 is particularly pertinent due to its association with various hematological malignancies, notably acute myeloid leukemia (AML). RUNX1T1 is often implicated in chromosomal translocations, most notably the RUNX1T1-RUNX1 fusion, which results from a t(8;21) translocation. This fusion protein promotes oncogenesis by altering normal hematopoietic differentiation, leading to the expansion of immature myeloid cells. Research has shown that RUNX1T1 can function as a transcriptional co-activator, modulating the expression of genes essential for blood cell development and survival. Furthermore, it interacts with other transcription factors and co-regulators, contributing to its role in cellular signaling pathways involved in cancer progression. Given its pivotal function in leukemogenesis, RUNX1T1 has emerged as a potential therapeutic target, and understanding its molecular mechanisms could pave the way for novel treatment strategies in AML. The ongoing research aims to elucidate the full spectrum of RUNX1T1's roles in both normal and malignant hematopoiesis, ultimately providing insights into better diagnostic and therapeutic approaches for leukemia patients.
